Pharmacogenomics: Tailoring Drugs to Genetic Profiles

Introduction

Pharmacogenomics is the study of how an individual's genetic makeup influences their response to drugs. This field integrates pharmacology and genomics to develop effective, safe medications and doses tailored to a patient's genetic profile [1, 2]. The fundamental premise is that interindividual variability in drug efficacy and toxicity is substantially attributable to inherited genetic polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters, and therapeutic targets [3, 4]. In veterinary medicine, the application of pharmacogenomic principles offers the potential to optimize therapeutic outcomes, reduce adverse drug reactions, and refine dosing regimens across diverse animal species and breeds.

Genetic Determinants of Drug Response

The pharmacokinetic and pharmacodynamic profile of a drug is modulated by a complex network of gene products. Variants in these genes can alter drug absorption, distribution, metabolism, and excretion (ADME) as well as the sensitivity of the drug target itself [4, 5].

Drug-Metabolizing Enzymes

The cytochrome P450 (CYP) superfamily constitutes the primary phase I drug-metabolizing enzyme system. Polymorphisms in CYP genes are among the most clinically significant pharmacogenetic variants [6, 7, 8].

CYP2C19 is a highly polymorphic enzyme responsible for the metabolism of numerous therapeutic agents. Variant alleles result in a spectrum of metabolizer phenotypes: poor metabolizers (PMs), intermediate metabolizers (IMs), extensive metabolizers (EMs), and ultrarapid metabolizers (UMs) [9, 7]. The distribution of CYP2C19 polymorphisms varies markedly across populations, influencing the selection and dosing of drugs such as certain antiplatelet agents and proton pump inhibitors [8].

CYP2D6 is another critical enzyme involved in the metabolism of approximately 25% of all drugs, including many antidepressants and antipsychotics [7, 10, 11]. The CYP2D6 gene locus exhibits extensive copy number variation and allelic diversity, leading to a wide range of metabolic capacities. Individuals classified as CYP2D6 PMs are at increased risk of drug accumulation and toxicity at standard doses, while UMs may experience therapeutic failure due to rapid drug clearance [7, 10].

Other important drug-metabolizing enzyme families include the N-acetyltransferases (NATs), thiopurine S-methyltransferase (TPMT), and uridine diphosphate glucuronosyltransferases (UGTs). Variants in these genes have been associated with altered drug toxicity profiles, particularly in the context of chemotherapeutic agents [12, 13, 14].

Drug Transporters and Targets

Genetic variants in drug transporter genes, such as those encoding P-glycoprotein (ABCB1) and organic anion transporting polypeptides (OATPs), can significantly affect drug disposition and tissue penetration [4, 5]. For example, a well-characterized deletion mutation in the canine ABCB1 gene (MDR1) results in a non-functional P-glycoprotein, leading to severe neurotoxicity from macrocyclic lactones such as ivermectin.

Polymorphisms in drug target genes, including receptors and ion channels, can alter drug binding affinity and downstream signaling. In the context of psychiatric and neurological disorders, variants in dopamine receptor genes (e.g., DRD2, DRD3) and serotonin transporter genes (e.g., SLC6A4) have been investigated for their influence on antipsychotic and antidepressant response [15, 16, 17].

Clinical Applications in Veterinary Medicine

The translation of pharmacogenomic principles into veterinary clinical practice is advancing, with several key areas of application.

Anesthesia and Analgesia

Genetic variability in drug-metabolizing enzymes and targets can profoundly affect the safety and efficacy of anesthetic and analgesic agents [18, 19]. For instance, polymorphisms in the CYP2C19 and CYP2D6 genes can influence the metabolism of opioids and benzodiazepines, altering the duration and intensity of their effects [20]. Similarly, variants in the mu-opioid receptor gene (OPRM1) have been associated with differential pain sensitivity and opioid requirements [20].

Antimicrobial and Antiparasitic Therapy

The efficacy and toxicity of antimicrobial and antiparasitic drugs can be modulated by host genetics. The ABCB1 mutation in certain dog breeds (e.g., Collies, Australian Shepherds) is a classic example of a pharmacogenetic trait with direct clinical relevance. Animals homozygous for the mutant allele are highly susceptible to neurotoxicity from ivermectin and related drugs. Preemptive genotyping for this variant is a practical application of pharmacogenomics in veterinary practice.

Oncology

Pharmacogenomics holds significant promise for tailoring chemotherapeutic regimens in veterinary oncology [21, 22]. Genetic variants in TPMT and UGT1A1 are associated with an increased risk of severe toxicity from thiopurines and irinotecan, respectively [12, 13]. Genome-wide association studies (GWAS) have identified loci associated with treatment-related adverse effects in pediatric acute lymphoblastic leukemia, providing a framework for similar studies in canine and feline cancers [12].

Immunosuppressive Therapy

In the context of transplant medicine and autoimmune disease management, genetic polymorphisms in the genes encoding calcineurin inhibitors (e.g., CYP3A5) and inosine monophosphate dehydrogenase (IMPDH) can influence the pharmacokinetics and pharmacodynamics of immunosuppressive agents such as cyclosporine and mycophenolate mofetil [5].

Computational and Machine Learning Approaches

The integration of machine learning (ML) and artificial intelligence (AI) with pharmacogenomics is accelerating the discovery and clinical implementation of genetic biomarkers [3, 16]. ML algorithms can analyze high-dimensional genomic data to identify complex, non-linear relationships between genetic variants and drug response phenotypes.

Predictive Modeling

Supervised learning methods, including random forests, support vector machines, and neural networks, have been employed to build predictive models of drug efficacy and toxicity [3, 16]. These models can integrate genomic, transcriptomic, and clinical data to generate individualized treatment recommendations. For example, ML approaches have been used to prioritize antidepressant drug prescription based on drug-induced gene expression profiles [23].

In Silico Prioritization

Computational frameworks that leverage drug-induced expression profiles and predicted gene expression can guide the selection of pharmacotherapeutic agents [23]. These in silico methods can reduce the need for trial-and-error prescribing, particularly in complex polygenic conditions.

Workflow for Pharmacogenomic Testing

The following Mermaid diagram illustrates a typical workflow for integrating pharmacogenomic testing into clinical decision-making.

graph TD
    A[Clinical Indication for Drug Therapy], > B{Pharmacogenomic Testing Indicated?}
    B, >|Yes| C[Collect Biological Sample (Blood/Buccal Swab)]
    B, >|No| D[Standard Dosing Regimen]
    C, > E[DNA Extraction and Genotyping]
    E, > F[Genotype Analysis: CYP2C19, CYP2D6, ABCB1, etc.]
    F, > G[Phenotype Assignment: PM, IM, EM, UM]
    G, > H[Integration with Clinical Decision Support System]
    H, > I[Personalized Drug and Dose Selection]
    I, > J[Monitor Therapeutic Response and Adverse Effects]
    J, > K[Adjust Regimen as Needed]
    K, > L[Optimized Clinical Outcome]

Challenges and Future Directions

Despite its potential, the widespread adoption of pharmacogenomics in veterinary medicine faces several challenges.

Validation and Standardization

The clinical validity and utility of many pharmacogenetic biomarkers remain to be rigorously established in veterinary species [4, 24]. Standardized genotyping platforms and phenotype assignment algorithms are needed to ensure reproducibility across laboratories [25].

Population-Specific Variants

The frequency and functional impact of pharmacogenetic variants can differ substantially across breeds and populations [26, 8]. Comprehensive characterization of genetic diversity in veterinary species is essential for the development of breed-specific dosing guidelines.

Education and Implementation

Integrating pharmacogenomics into veterinary curricula and clinical workflows requires targeted education for practitioners [27]. The development of user-friendly clinical decision support tools can facilitate the translation of genomic data into actionable prescribing recommendations.

Ethical and Regulatory Considerations

The use of genetic information for therapeutic decision-making raises ethical issues related to privacy, informed consent, and potential for genetic discrimination [2]. Clear regulatory frameworks are needed to govern the use of pharmacogenomic tests in veterinary practice.

Conclusion

Pharmacogenomics represents a paradigm shift in veterinary therapeutics, moving from a one-size-fits-all approach to a precision medicine model. By elucidating the genetic determinants of drug response, this field enables the selection of optimal drugs and doses for individual patients, thereby maximizing efficacy and minimizing toxicity. Continued research into the pharmacogenomic landscape of veterinary species, coupled with advances in computational biology and clinical decision support, will be critical for the successful integration of these principles into routine clinical practice.

References

[1] Charlab R, Zhang L. Pharmacogenomics: historical perspective and current status. Methods Mol Biol. 2013. URL: https://pubmed.ncbi.nlm.nih.gov/23824846/

[2] Noah L. The coming pharmacogenomics revolution: tailoring drugs to fit patients' genetic profiles. Jurimetrics. 2002. URL: https://pubmed.ncbi.nlm.nih.gov/17333591/

[3] Jakka AL, Chacko RM, Vasam M et al. From genomics to clinic: the transformative impact of AI in pharmacogenomics and personalized medicine. Pharmacogenomics. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41277106/

[4] Arbitrio M, Di Martino MT, Scionti F et al. Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives. High Throughput. 2018. URL: https://pubmed.ncbi.nlm.nih.gov/30567415/

[5] Cattaneo D, Perico N, Remuzzi G. From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. Am J Transplant. 2004. URL: https://pubmed.ncbi.nlm.nih.gov/14961981/

[6] Eitan LA, Khair IY, Alahmad S. Drug Metabolizing Enzymes: An Exclusive Guide into Latest Research in Pharmaco-genetic Dynamics in Arab Countries. Curr Drug Metab. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/39377381/

[7] Brouwer JMJL, Wardenaar KJ, Nolte IM et al. Association of CYP2D6 and CYP2C19 metabolizer status with switching and discontinuing antidepressant drugs: an exploratory study. BMC Psychiatry. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38797832/

[8] Li J, Wang Y, Wang H. Distribution of CYP2C19 polymorphisms in Mongolian and Han nationals and the choice of specific antiplatelet drugs. Int J Clin Pharm. 2017. URL: https://pubmed.ncbi.nlm.nih.gov/28597175/

[9] Dodson C, Dulko D. Using the genotype selection interface: a clinical case study for CYP2C19. J Am Assoc Nurse Pract. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40493688/

[10] Korošec Hudnik L, Blagus T, Redenšek Trampuž S et al. Case report: Avoiding intolerance to antipsychotics through a personalized treatment approach based on pharmacogenetics. Front Psychiatry. 2024. URL: https://pubmed.ncbi.nlm.nih.gov/38566958/

[11] Naumovska Z, Nestorovska AK, Filipce A et al. Pharmacogenetics and antipsychotic treatment response. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015. URL: https://pubmed.ncbi.nlm.nih.gov/26076775/

[12] Franca R, Zudeh G, Lucafò M et al. Genome wide association studies for treatment-related adverse effects of pediatric acute lymphoblastic leukemia. WIREs Mech Dis. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/33016644/

[13] Gervasini G, Vagace JM. Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia. Front Genet. 2012. URL: https://pubmed.ncbi.nlm.nih.gov/23189085/

[14] Loni L, De Braud F, Zinzani PL et al. Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma. Leuk Lymphoma. 2003. URL: https://pubmed.ncbi.nlm.nih.gov/15202534/

[15] Ayuso P, Jiménez-Jiménez FJ, Gómez-Tabales J et al. An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson's disease. Expert Opin Drug Metab Toxicol. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37599424/

[16] Del Casale A, Sarli G, Bargagna P et al. Machine Learning and Pharmacogenomics at the Time of Precision Psychiatry. Curr Neuropharmacol. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37559539/

[17] Fortinguerra S, Sorrenti V, Giusti P et al. Pharmacogenomic Characterization in Bipolar Spectrum Disorders. Pharmaceutics. 2019. URL: https://pubmed.ncbi.nlm.nih.gov/31877761/

[18] Searle R, Hopkins PM. Pharmacogenomic variability and anaesthesia. Br J Anaesth. 2009. URL: https://pubmed.ncbi.nlm.nih.gov/19482856/

[19] Landau R, Kraft JC. Pharmacogenetics in obstetric anesthesia. Curr Opin Anaesthesiol. 2010. URL: https://pubmed.ncbi.nlm.nih.gov/20440109/

[20] Bugada D, Lorini LF, Fumagalli R et al. Genetics and Opioids: Towards More Appropriate Prescription in Cancer Pain. Cancers (Basel). 2020. URL: https://pubmed.ncbi.nlm.nih.gov/32708424/

[21] Di Francia R, De Monaco A, Saggese M et al. Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy. Curr Cancer Drug Targets. 2018. URL: https://pubmed.ncbi.nlm.nih.gov/28183252/

[22] Vella N, Aiello M, Russo AE et al. 'Genetic profiling' and ovarian cancer therapy (review). Mol Med Rep. 2011. URL: https://pubmed.ncbi.nlm.nih.gov/21687948/

[23] Shoaib M, Giacopuzzi E, Pain O et al. Investigating an in silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression. Pharmacogenomics J. 2021. URL: https://pubmed.ncbi.nlm.nih.gov/32943772/

[24] Nagy ZB, Csanád M, Tóth K et al. Current concepts in the genetic diagnostics of rheumatoid arthritis. Expert Rev Mol Diagn. 2010. URL: https://pubmed.ncbi.nlm.nih.gov/20629510/

[25] Deeken J. The Affymetrix DMET platform and pharmacogenetics in drug development. Curr Opin Mol Ther. 2009. URL: https://pubmed.ncbi.nlm.nih.gov/19479659/

[26] Samarasinghe SR, Hoy W, Jadhao S et al. The pharmacogenomic landscape of an Indigenous Australian population. Front Pharmacol. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37284308/

[27] Venugopal ML, Yong FR, Krzyzaniak N et al. Mapping Australian pharmacy school curricula for content related to pharmacogenomics. Explor Res Clin Soc Pharm. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/36299640/

[28] Roberts B, Cooper Z, Miljevic A et al. PharmacoGENEtics in Youth Depression (GENE-YD) Study protocol: a pilot triple-blinded randomised controlled trial using pharmacogenetics to tailor antidepressant treatment in young Australians. BMJ Open. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41218941/

[29] Shorbaji A, Pushparaj PN, Al-Ghafari AB et al. A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications. NPJ Genom Med. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40640196/

[30] Kayani M, Sangeetha GK, Sarangi S et al. Pharmacogenomics and its Role in Cardiovascular Diseases: A Narrative Literature Review. Curr Cardiol Rev. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39901689/

[31] Wysocki T, Paradowska-Gorycka A. Pharmacogenomics of Anti-TNF Treatment Response Marks a New Era of Tailored Rheumatoid Arthritis Therapy. Int J Mol Sci. 2022. URL: https://pubmed.ncbi.nlm.nih.gov/35216481/

[32] Weeke PE. Pharmacogenetics in Cardiovascular Medicine. Adv Pharmacol. 2018. URL: https://pubmed.ncbi.nlm.nih.gov/29801582/

[33] Aceti A, Gianserra L, Lambiase L et al. Pharmacogenetics as a tool to tailor antiretroviral therapy: A review. World J Virol. 2015. URL: https://pubmed.ncbi.nlm.nih.gov/26279982/

[34] Di Paolo A, Polillo M, Lastella M et al. Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs. Expert Opin Drug Metab Toxicol. 2015. URL: https://pubmed.ncbi.nlm.nih.gov/26037261/

[35] Ortega VE, Meyers DA, Bleecker ER. Asthma pharmacogenetics and the development of genetic profiles for personalized medicine. Pharmgenomics Pers Med. 2015. URL: https://pubmed.ncbi.nlm.nih.gov/25691813/

[36] Loutradis D, Theofanakis C, Anagnostou E et al. Genetic profile of SNP(s) and ovulation induction. Curr Pharm Biotechnol. 2012. URL: https://pubmed.ncbi.nlm.nih.gov/21657995/

[37] Rego-Pérez I, Fernández-Moreno M, Carreira-García V et al. [Gene polymorphisms and pharmacogenetics in Rheumatoid Arthritis]. Reumatol Clin. 2009. URL: https://pubmed.ncbi.nlm.nih.gov/21794628/

[38] Maitland-van der Zee AH, de Boer A, Leufkens HG. The interface between pharmacoepidemiology and pharmacogenetics. Eur J Pharmacol. 2000. URL: https://pubmed.ncbi.nlm.nih.gov/11134664/